News|Articles|July 2, 2003

Pharmaceutical Technology

  • Pharmaceutical Technology-07-02-2003
  • Volume 27
  • Issue 7

Capacity Worries Fade for Biomanufacturing

Author(s)Jim Miller

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.